

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/849,374	05/19/2004	Bjorn Olstad	15-DS-00549 (MHM 13109US0	6522	
	7590 09/19/200 S HELD & MALLOY,	•	EXAMINER		
500 WEST MADISON STREET			CHAO, ELMER M		
SUITE 3400 CHICAGO, IL	60661		ART UNIT PAPER NUMBER		
,			3737		
			MAIL DATE	DELIVERY MODE	
			09/19/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•	U	+	
	Application No.	Applicant(s)	
	10/849,374	OLSTAD, BJORN	
Office Action Summary	Examiner	Art Unit	
	Elmer Chao	3737	
The MAILING DATE of this communication app	ears on the cover sheet	with the correspondence address	
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v. - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUI 36(a). In no event, however, may will apply and will expire SIX (6) M , cause the application to become	NICATION. a reply be timely filed ONTHS from the mailing date of this communication ABANDONED (35 U.S.C. § 133).	
Status			
 1) Responsive to communication(s) filed on <u>07 Fe</u> 2a) This action is FINAL. 2b) This 3) Since this application is in condition for alloward closed in accordance with the practice under E 	action is non-final.		is
Disposition of Claims			
4) Claim(s) 1-21 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) 1-21 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	wn from consideration:		
Application Papers			
9)☐ The specification is objected to by the Examine 10)☒ The drawing(s) filed on 10 September 2004 is/a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11)☐ The oath or declaration is objected to by the Examine 11.	are: a)⊠ accepted or b drawing(s) be held in abey tion is required if the drawi	vance. See 37 CFR 1.85(a). ng(s) is objected to. See 37 CFR 1.121	(d).
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in rity documents have be u (PCT Rule 17.2(a)).	Application No en received in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 7/26/2004 & 2/7/2005.	Paper N	w Summary (PTO-413) lo(s)/Mail Date of Informal Patent Application	

Application/Control Number: 10/849,374

Art Unit: 3737

DETAILED ACTION

Double Patenting

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 1, 3, 4, 5, and 7 are provisionally rejected on the ground of nonstatutory double patenting over claims 6, 9, and 11-16 of copending Application No. 11/082,540. This is a provisional double patenting rejection since the conflicting claims have not yet been patented.

The subject matter claimed in the instant application is fully disclosed in the referenced copending application and would be covered by any patent granted on that copending application since the referenced copending application

Application/Control Number: 10/849,374

Art Unit: 3737

and the instant application are claiming common subject matter, as follows: a method of using an ultrasound machine including locating at least one anatomical landmark; locating at least one clinically relevant location based on the at least one anatomical landmark; extracting clinically relevant information from said at least one clinically relevant location within the heart; and displaying indicia overlaying said at least one clinically relevant location.

Furthermore, there is no apparent reason why applicant would be prevented from presenting claims corresponding to those of the instant application in the other copending application. See *In re Schneller*, 397 F.2d 350, 158 USPQ 210 (CCPA 1968). See also MPEP § 804.

3. Claims 1-5, 7, 10, and 11 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-11 of copending Application No. 10/848,721. Although the conflicting claims are not identical, they are not patentably distinct from each other because the conflicting claims are narrower in scope than the present application claims.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35
U.S.C. 102 that form the basis for the rejections under this section made in this
Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 5. Claims 1-21 are rejected under 35 U.S.C. 102(b) as being anticipated by Roundhill et al. (U.S. 6,447,453 B1; also see Publication U.S. 2002/0072672 A1).

Regarding claims 1-4, and 7-10, Roundhill et al. teach a method for using an ultrasound machine comprising locating at least one anatomical landmark within the cardiac structure and generating position information of said at least one anatomical landmark comprising the apex of the heart (Fig. 4); locating at least one clinically relevant location within the heart based on said position information of said at least one anatomical landmark (Fig. 8, see the border of the LV); and extracting clinically relevant information from said at least one clinically relevant location within the heart, wherein the clinically relevant information comprises Doppler profile information (col. 10, lines 12-15), wherein the extracting involves presetting at least one m-mode, Doppler sample volume, and region-of-interest (col. 9, line 62 – col. 10, line 51); and displaying indicia overlaying said at least one clinically relevant location on a display of said ultrasound machine (Fig. 5, Items 26, 36, & 46; Fig. 11, Item 100).

Art Unit: 3737

Regarding **claim 5**, Roundhill et al. teach the clinically relevant location being the LV portion of the heart (see Fig. 13a).

Regarding **claim 6**, Roundhill et al. teach that locating at least one clinically relevant location includes performing edge detection of said at least one myocardial segment of the heart to locate endocardium of said at least one myocardial segment (see Fig. 12; claim 12; col. 11, line 58 – col. 12, line 10).

Regarding **claims 11 and 12,** Roundhill et al. teach tracking the apex and control points as the heart is beating and automatically drawing cardiac borders (col. 10, lines 52 – 67; col. 13, lines 12-31).

Regarding **claims 13-21**, Roundhill et al. teach the method steps as discussed above which would necessitate the presence of the corresponding apparatus parts used in the method steps.

Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elmer Chao whose telephone number is (571)272-0674. The examiner can normally be reached on 9am-4pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on (571)272-4956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3737

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

EC 9/6/2007